PMID- 11516202
OWN - NLM
STAT- MEDLINE
DCOM- 20010920
LR  - 20181130
IS  - 0022-4804 (Print)
IS  - 0022-4804 (Linking)
VI  - 100
IP  - 1
DP  - 2001 Sep
TI  - Ex vivo host response to gastrointestinal cancer cells presented by autologous 
      dendritic cells.
PG  - 32-8
AB  - BACKGROUND: Dendritic cells (DCs) capture apoptotic tumors and cross-present 
      their antigens in the MHC class I and class II pathways for recognition by CD4+ 
      and CD8+ T lymphocytes. Here we have tested the ability of fresh surgically 
      resected colon and gastric cancer tumors to specifically activate host T 
      lymphocytes when presented by autologous DCs. METHODS: DCs derived from adherent 
      blood mononuclear cells of five patients, after a 7-day culture with GM-CSF and 
      IL-4, were exposed to apoptotic autologous tumor (AAT) or apoptotic autologous 
      peritumor normal (AAN) cells and cultured 24 h with monocyte-conditioned medium 
      to achieve full DC maturation. Tumor-specific response was evaluated as 
      single-cell cytokine release in an enzyme-linked immunospot (ELISPOT) and as 
      cytotoxicity in a cold target inhibition (51)Cr-release assay. RESULTS: AAT-DCs 
      induced specific IFN-gamma by T lymphocytes of two patients (rectal and gastric 
      cancer), whereas in another two patients (rectal and gastric cancer) this 
      response was depressed with a similar tumor-specific pattern and in one patient 
      (rectal cancer) there was no response. Activation of IFN-gamma release was 
      accompanied by tumor cytotoxicity and both responses were enhanced by IL-12, 
      indicating the functional integrity of patients' lymphocytes. CONCLUSION: These 
      data show that T-cell memory against rectal/gastric carcinoma antigens can be 
      triggered by tumor-loaded autologous DCs. However, escape mechanisms may exist 
      among tumors of the same histological origin that can inhibit this host response. 
      A DC-based antitumor immunological monitoring assay with autologous tumor 
      biopsies may allow patients to be screened to determine those who are suitable 
      candidates for immune-based immunotherapy.
CI  - Copyright 2001 Academic Press.
FAU - Galetto, A
AU  - Galetto A
AD  - Department of Oncology, Unity of Oncological Surgery, Azienda Ospedaliera San 
      Giovanni, Turin, Italy.
FAU - Contarini, M
AU  - Contarini M
FAU - Sapino, A
AU  - Sapino A
FAU - Cassoni, P
AU  - Cassoni P
FAU - Consalvo, E
AU  - Consalvo E
FAU - Forno, S
AU  - Forno S
FAU - Pezzi, C
AU  - Pezzi C
FAU - Barnaba, V
AU  - Barnaba V
FAU - Mussa, A
AU  - Mussa A
FAU - Matera, L
AU  - Matera L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Antigens, Neoplasm)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - *Adenocarcinoma
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/*immunology
MH  - Carcinoma, Signet Ring Cell
MH  - *Colorectal Neoplasms
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Interferon-gamma/immunology/metabolism
MH  - Interleukin-12/pharmacology
MH  - *Stomach Neoplasms
MH  - T-Lymphocytes, Cytotoxic/drug effects/immunology/metabolism
MH  - Tumor Cells, Cultured/cytology/immunology
EDAT- 2001/08/23 10:00
MHDA- 2001/09/21 10:01
CRDT- 2001/08/23 10:00
PHST- 2001/08/23 10:00 [pubmed]
PHST- 2001/09/21 10:01 [medline]
PHST- 2001/08/23 10:00 [entrez]
AID - S0022-4804(01)96158-X [pii]
AID - 10.1006/jsre.2001.6158 [doi]
PST - ppublish
SO  - J Surg Res. 2001 Sep;100(1):32-8. doi: 10.1006/jsre.2001.6158.